On 21 March 2016, orphan designation (EU/3/16/1633) was granted by the European Commission to Diamond BioPharm Limited, United Kingdom for fosbretabulin tromethamine for the treatment of gastro-entero-pancreatic neuroendocrine tumours.
The sponsorship was transferred to Diamond ROC EOOD, Bulgaria, in March 2019.
The sponsorship was transferred to Diamond Pharma Services Ireland Limited in February 2020.
|Disease / condition||
Treatment of gastro-entero-pancreatic neuroendocrine tumours
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.